Terug
11
Ook genoteerd als
ARHCF
OTC
Dagbereik
€ 16,01
€ 16,23
52-Weeksbereik
€ 12,42
€ 16,39
Volume
58
50D / 200D Gem.
€ 15,84
/
€ 15,54
Vorige Slotkoers
€ 16,23
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 5,7 | 3,7 |
| Net Margin % | 0,9 | 3,8 |
| Rev Growth 5Y % | 3,3 | 10,0 |
| D/E | 0,1 | 0,2 |
Belangrijkste Punten
Revenue grew 3,27% annually over 5 years — modest growth
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -10,87B
P/E of 0,11 — trading at a low valuation
Capital efficient — spends only 0,56% of revenue on capex
Groei
Revenue Growth (5Y)
3,27%
Revenue (1Y)3,59%
Earnings (1Y)-7,33%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
5,70%
ROIC5,52%
Net Margin0,93%
Op. Margin1,29%
Veiligheid
Debt / Equity
0,07
Current Ratio1,22
Interest Coverage136,49
Waardering
P/E Ratio
0,11
P/B Ratio0,01
EV/EBITDA-3,64
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3,59% | Revenue Growth (3Y) | 4,80% |
| Earnings Growth (1Y) | -7,33% | Earnings Growth (3Y) | 3,06% |
| Revenue Growth (5Y) | 3,27% | Earnings Growth (5Y) | 2,83% |
| Profitability | |||
| Revenue (TTM) | 2,96T | Net Income (TTM) | 27,39B |
| ROE | 5,70% | ROA | 1,90% |
| Gross Margin | 7,22% | Operating Margin | 1,29% |
| Net Margin | 0,93% | Free Cash Flow (TTM) | -10,87B |
| ROIC | 5,52% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,07 | Current Ratio | 1,22 |
| Interest Coverage | 136,49 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 0,11 | P/B Ratio | 0,01 |
| P/S Ratio | 0,00 | PEG Ratio | -3,19 |
| EV/EBITDA | -3,64 | Dividend Yield | 0,03% |
| Market Cap | 2,95B | Enterprise Value | -138,59B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,96T | 2,86T | 2,70T | 2,59T | 2,60T |
| Net Income | 27,39B | 29,56B | 25,79B | 32,18B | 24,50B |
| EPS (Diluted) | 147,54 | 154,13 | 127,42 | 153,57 | 115,75 |
| Gross Profit | 213,93B | 206,37B | 192,09B | 187,47B | 175,54B |
| Operating Income | 38,08B | 38,46B | 30,15B | 29,09B | 20,67B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,44T | 1,45T | 1,34T | 1,30T | 1,32T |
| Total Liabilities | 957,63B | 967,77B | 851,52B | 832,16B | 826,70B |
| Shareholders' Equity | 481,79B | 479,60B | 488,09B | 471,59B | 489,74B |
| Total Debt | 35,55B | 34,94B | 3,86B | 5,04B | 6,17B |
| Cash & Equivalents | 177,09B | 213,76B | 160,12B | 180,44B | 170,28B |
| Current Assets | 1,09T | 1,12T | 1,03T | 1,02T | 992,48B |
| Current Liabilities | 894,96B | 906,99B | 825,73B | 802,81B | 783,93B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#571 of 708
Recente Activiteit
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026